,18,19 On the basis of this evidence, we now hypothesize that STK25 is an important mediator in the complex and integrated molecular network driving the initiation and progression of NASH-related HCC, and a potential target for anti-HCC therapy. This evidence concerns the gene STK25 and metabolic dysfunction-associated steatohepatitis.